This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Esomeprazole Strontium Delayed-Release
Hanmi Pharmaceutical Co., Ltd.
Drug Names(s): esomeprazole strontium delayed-release
Esomeprazole Strontium is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of H+/K+-ATPase in the gastric parietal cell. By acting specifically on the proton pump, esomeprazole blocks the final step in acid production, thus reducing gastric acidity.
Esomeprazole Strontium is a delayed-release, bioequivalent formulation of Nexium.
Hanmi and Amneal
In January 2013, Amneal announced that it has entered into a license and distribution agreement with Hanmi to acquire exclusive distribution rights to Hanmi's new drug application (NDA) for esomeprazole strontium delayed-release capsules.
Partners: Amneal Pharmaceuticals, LLC
Esomeprazole Strontium Delayed-Release News
Pink Sheet FDA’s ANDA Approvals
Additional information available to subscribers only: